Methadone Hydrochloride

OSLO, Norway, July 15, 2025 /PRNewswire/ -- Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired products (the "Transaction"). Navamedic is pleased to announce that the Transaction has today been successfully completed. The Acquisition encompasses dne pharma's business, including product portfolio, key employees and all essential contracts of the business, intellectual property, licenses, and distribution agreements. The product portfolio includes prominent products such as Ventizolve® (intranasal naloxone spray for opioid overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for opioid substitution therapy. The acquired business will be integrated into Navamedic's existing commercial platform, enabling rapid market access and geographic expansion across the Nordics and selected European markets. "This acquisition represents a significant step in our strategic expansion into the rapidly growing field of addiction treatment and is well aligned with our long-term growth ambitions. Thanks to the strong collaboration among all parties involved, the transaction was completed in a smooth and efficient manner. We are pleased that the General Meeting unanimously approved the Rights Issue yesterday, and we are sincerely grateful for the continued support of Kistefos and the other underwriters," said Kathrine Gamborg Andreassen, CEO of Navamedic. The Acquisition is financed through a combination of new debt in the amount of NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights issue approved at an extraordinary general meeting of Navamedic on 14 July (the "Rights Issue"). Navamedic has been assisted by DNB Carnegie a part of DNB Bank ASA ("DNB Carnegie") and Advokatfirmaet Thommessen ("Thommessen") in connection with the Acquisition, and Navamedic has been granted a bridge loan from Nordea enabling completion of the Acquisition before completion of the Rights Issue. Navamedic has retained DNB Carnegie, and Nordea Corporate Finance, a part of Nordea Bank Abp, filial i Norge as managers and Thommessen as legal advisors for the Rights Issue. "We are very pleased closing this transaction with Navamedic and we are confident that the Navamedic team will continue to grow the opioid substitution business developed by dne pharma, in particular the Ventizolve® products," says Geir Ove Engeset, CEO of dne pharma as. For further information, please contact: Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: [email protected], or Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit About dne pharma/Pharma Production Prior to closing of the Transaction, dne pharma was a Norwegian developer and distributor of addiction and pain therapies, including opioid substitution treatments and emergency overdose medications. dne pharma's wholly owned subsidiary, Pharma Production AS, will continue to manufacture and supply the product portfolio recently acquired by Navamedic, as well as concentrate on contract manufacturing and development services, including analytical services, supporting the long-term need for national pharmaceutical production capacity. . This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This information was brought to you by Cision WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Relmada originally licensed esmethadone in 2018 for $180,000 upfront and subsequent payments of $45,000 every three months.\n After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset they were testing. The Florida-based biotech terminated its license agreement for esmethadone on July 7, with all of their obligations under the deal set to expire on Oct. 5.Relmada has tested esmethadone, which it called REL-1017, in several phase 3 trials for various major depressive disorder (MDD) indications. The prospect flopped in just about every one of them.In October 2022, REL-1017 failed to top placebo as an MDD monotherapy in the phase 3 RELIANCE III trial. Another stumble followed just months later, this time as an adjunctive MDD treatment in late-stage RELIANCE I, which the company attributed to “a limited number of high-enrolling sites with unplausible placebo response.”Esmethadone did better in a 2023 open-label trial, successfully improving depression symptoms, but the study had no placebo arm.The third phase 3 strike for REL-1017 came in December 2024, when Relmada revealed that its RELIANCE II trial, which was testing esmethadone as an adjunctive treatment for MDD, was unlikely to hit its primary endpoint. As a result, Relmada scrapped the trial and another related study, RELIGHT, which used a similar design, and announced plans to pursue strategic alternatives like a merger or sale of the company.Esmethadone is a component of methadone, the pain and substance use medication. Relmada originally licensed the candidate in January 2018 from Charles Inturrisi, Ph.D., and Paolo Manfredi, M.D., for an upfront fee of $180,000. Inturrisi, a pharmacologist at Cornell University, originally developed esmethadone and licensed it to Medeor, which Manfredi co-founded. Relmada merged with Medeor in 2013.Manfredi’s Medeor is not to be confused with kidney transplant company Medeor Therapeutics. As part of the licensing deal, Relmada was paying Inturrisi and Manfredi $45,000 every three months, a stipulation that was set to continue until esmethadone was sold as a commercial product or the patent on it expired.Relmada is now focused on making strategic asset acquisitions, according to its website, as well as advancing remaining assets NDV-01 and sepranolone. NDV-01 is currently being tested in an open-label phase 2 trial in non-muscle invasive bladder cancer, while sepranolone is a phase 2 Tourette syndrome asset that Relmada purchased in February from Asarina Pharma.